NasdaqGM:BCAXBiotechs
Should Bicara’s Phase 1/1b Ficerafusp Alfa Survival Data Prompt Action From Bicara Therapeutics (BCAX) Investors?
In May 2026, Bicara Therapeutics reported three-year follow-up data from its Phase 1/1b study of ficerafusp alfa plus pembrolizumab in first-line recurrent or metastatic HPV‑negative head and neck squamous cell carcinoma, showing deep and durable responses across multiple dose cohorts with a generally well-tolerated safety profile and no new safety signals.
A particularly interesting finding was that the 1,500mg weekly cohort showed an estimated three-year overall survival rate roughly twice...